B. Metzler seel. Sohn & Co. AG Cuts Stake in Biogen Inc. $BIIB

B. Metzler seel. Sohn & Co. AG decreased its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 58.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,258 shares of the biotechnology company's stock after selling 17,467 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Biogen were worth $2,648,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of BIIB. BlackRock Inc. purchased a new position in shares of Biogen in the second quarter valued at $3,453,878,000. Primecap Management Co. CA acquired a new stake in shares of Biogen during the second quarter valued at about $3,274,304,000. Norges Bank acquired a new stake in shares of Biogen during the fourth quarter valued at about $464,408,000. Boston Partners purchased a new stake in shares of Biogen during the fourth quarter worth about $302,815,000. Finally, Legal & General Group Plc acquired a new position in shares of Biogen in the second quarter worth about $322,640,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Zacks Research upgraded Biogen from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. Wall Street Zen downgraded shares of Biogen from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Evercore assumed coverage on shares of Biogen in a report on Friday, May 15th. They issued an "outperform" rating on the stock. Oppenheimer reaffirmed an "outperform" rating and set a $300.00 target price on shares of Biogen in a report on Wednesday, July 29th. Finally, Weiss Ratings downgraded Biogen from a "hold (c)" rating to a "hold (c-)" rating in a report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $228.50.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Long-term Dravet syndrome data support zorevunersen. Biogen and Stoke Therapeutics reported four-year Phase 1/2a extension data showing durable seizure reductions, including reductions in severe seizure types associated with sudden unexpected death in epilepsy, as well as continued improvements in cognition, behavior and quality of life. The results strengthen the potential for zorevunersen to become a disease-modifying treatment, though it remains investigational. Stoke and Biogen unveil long-term zorevunersen data
• Positive Sentiment: LEQEMBI gained a major China regulatory approval. China’s National Medical Products Administration approved the once-weekly subcutaneous autoinjector formulation of LEQEMBI for initiation treatment in early Alzheimer’s disease. At-home dosing could improve patient convenience, reduce infusion-center burdens and broaden adoption in a large and growing market. Eisai leads development and commercialization, with Biogen sharing economics under their collaboration. Biogen and Eisai announce China LEQEMBI approval
• Positive Sentiment: U.S. patients can now access weekly at-home LEQEMBI injections. Biogen and Eisai launched LEQEMBI IQLIK in the United States for eligible early Alzheimer’s patients, offering initiation and maintenance treatment through a pre-filled syringe or autoinjector. The new delivery option may lower barriers to treatment and support future product demand.
• Neutral Sentiment: Investors are assessing valuation after a strong rally. A valuation analysis argued that BIIB could be materially below estimated discounted-cash-flow value, but also noted that earnings-based multiples make the shares appear expensive. This conflicting signal may be contributing to caution after the stock’s substantial one-year gain.
• Negative Sentiment: Execution and safety risks remain. Zorevunersen’s data are from open-label early-stage studies and require confirmation in later trials. LEQEMBI’s subcutaneous formulation also carries injection-related reactions and still requires MRI monitoring for amyloid-related imaging abnormalities, potentially limiting uptake.

Biogen Price Performance

NASDAQ BIIB opened at $220.83 on Friday. Biogen Inc. has a 12 month low of $135.39 and a 12 month high of $225.80. The firm has a market capitalization of $32.63 billion, a PE ratio of 39.08, a P/E/G ratio of 2.48 and a beta of 0.17. The company's 50 day simple moving average is $209.53 and its 200 day simple moving average is $196.62. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB - Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts' consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same period in the prior year, the firm posted $5.47 earnings per share. The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts forecast that Biogen Inc. will post 12.39 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source